terfenadine has been researched along with ritonavir in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.88) | 18.2507 |
2000's | 9 (52.94) | 29.6817 |
2010's | 7 (41.18) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Rodrigues, AD; Wong, SL | 1 |
Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
Bourbeau, M; Cameron, DW; Campbell, P; Chauhan, BM; Foster, BC; Seguin, I; van Heeswijk, RP | 1 |
Alfaro, RM; Davey, RT; Formentini, E; Penzak, SR; Robertson, SM; Voell, J | 1 |
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D | 1 |
Banba, H; Takayama, K; Takeda-Morishita, M; Tomaru, A | 1 |
Ando, Y; Deguchi, M; Hirota, T; Ieiri, I; Irie, S; Izumi, N; Kanda, E; Kimura, M; Kotani, N; Kusuhara, H; Maeda, K; Matsuguma, K; Matsuki, S; Morishita, M; Okuzono, T; Sugiyama, Y; Tsunemitsu, S; Yamane, N | 1 |
1 review(s) available for terfenadine and ritonavir
Article | Year |
---|---|
Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience.
Topics: Animals; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Drug Evaluation, Preclinical; Drug Interactions; Humans; Isoenzymes; Microsomes, Liver; Pharmaceutical Preparations; Ritonavir; Terfenadine | 1997 |
4 trial(s) available for terfenadine and ritonavir
Article | Year |
---|---|
Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Drug Combinations; Drug Interactions; Female; Genotype; Histamine H1 Antagonists; HIV Protease Inhibitors; Humans; Liver; Lopinavir; Male; Middle Aged; Organic Anion Transporters; Pyrimidinones; Ritonavir; Terfenadine; Time Factors | 2006 |
Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Ginkgo biloba; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Phytotherapy; Plant Extracts; Protease Inhibitors; Pyrimidinones; Ritonavir; Terfenadine | 2008 |
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Topics: Adult; Alfentanil; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Intestines; Liver; Male; Methadone; Narcotics; Pupil; Ritonavir; Stereoisomerism; Terfenadine | 2008 |
Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Humans; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Organic Anion Transporters; Pravastatin; Ritonavir; Saquinavir; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2013 |
12 other study(ies) available for terfenadine and ritonavir
Article | Year |
---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Chromatography, High Pressure Liquid; Depression, Chemical; Drug Interactions; Drug Stability; Fluorometry; Histamine H1 Antagonists; Humans; In Vitro Techniques; Kinetics; Rhodamines; Ritonavir; Terfenadine; Time Factors; Verapamil | 2002 |
Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Inactivation, Metabolic; Mice; Microsomes; Midazolam; Pravastatin; Ritonavir; Saquinavir; Terfenadine | 2013 |